浆细胞病家族易感性的前瞻性研究
该研究在2017至2019年单中心连续纳入864例浆细胞病患者,对其一级和二级亲属进行血清蛋白电泳、免疫固定电泳和游离轻链筛查,并以配偶为对照。共筛查2481名家庭成员,98个家族(11.3%)检出至少1例额外的单克隆丙种球蛋白病,筛查新检出41例(每家族产出率4.7%)。结论确认浆细胞病存在家族易感性,受累家族成员风险至少为对照组的2倍。
要点
- 864个受累家族中11.3%检出至少1例额外单克隆丙种球蛋白病成员。
- 筛查新检出41例单克隆丙种球蛋白病,每家族产出率4.7%。
- 兄弟姐妹及二级亲属发生率4.5%,对照组为2.6%。
核心结论
- 大型前瞻性研究确认浆细胞病存在家族易感性,受累家族中超过11%有多个成员携带单克隆丙种球蛋白病。
- 受累家族成员发生浆细胞病的风险至少为对照组的2倍。
- 对浆细胞病患者亲属进行主动筛查可能有助于早期诊断、适当监测和及时干预。
研究设计与样本
- 2017至2019年单中心连续纳入1084例浆细胞病患者,其中864例符合条件并同意其一级和二级亲属接受筛查。
- 为所有患者绘制详细家系图,并对亲属进行血清蛋白电泳、免疫固定电泳和游离轻链检测筛查。
- 配偶作为对照组同样接受筛查;共筛查2481名家庭成员,中位年龄63岁。
主要发现
- 864个筛查家族中,98个(11.3%)检出至少1例额外的单克隆丙种球蛋白病家庭成员。
- 2.1%的家族存在浆细胞病或其他B细胞恶性肿瘤阳性病史。
- 筛查过程新检出41例单克隆丙种球蛋白病,每家族产出率4.7%。
- 兄弟姐妹及二级亲属中发生率为4.5%,对照组为2.6%。
临床怎么用
- 对浆细胞病患者的一级和二级亲属可考虑主动筛查单克隆丙种球蛋白病,以促进早期诊断和监测。
局限性
- 研究为单中心设计,结果外推需谨慎。
- 摘要未报告筛查的具体随访时长及干预结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Plasma cell dyscrasias (PCDs) exhibit familial aggregation, yet data quantifying this risk through active screening remain limited. Herein, we designed this study to identify and quantify the familial risk of PCDs by detailed family trees and screening all first- and second-degree relatives of affected patients. We approached 1084 consecutive patients with PCDs at a single center between 2017 and 2019, of whom 864 eligible index patients provided consent to first- and second-degree relative screening. Detailed pedigrees were created for all patients, and screening with serum protein electrophoresis, immunofixation, and free light chain assays was performed. Spouses were also screened as a control group. In total, 2481 family members were screened; median age was 63 years. At least 1 additional family member with a monoclonal gammopathy (MG) was detected in 98 (11.3%) of the 864 screened families. A positive history of PCD or other B-cell malignancy was present in 2.1% of the families. Notably, the screening process identified 41 new cases of MGs (4.7% yield per family). The incidence was 4.5% among siblings and second-degree relatives compared to 2.6% in the control group. In conclusion, this large prospective study confirms a familial predisposition to PCDs, revealing that >11% of the affected families have multiple members with MGs, corresponding to at least twice the risk of PCDs among members of affected families. These findings support the potential clinical value of active screening for relatives of patients with PCDs to facilitate early diagnosis, appropriate monitoring, and prompt intervention.
引用
- Gavriatopoulou M, Andrikopoulou A, Ntanasis-Stathopoulos I, et al. A prospective study of familial predisposition to plasma cell dyscrasias. Blood Adv. 2026. PMID: 42478698. doi:10.1182/bloodadvances.2026020394
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。